Payment overview · 2025
General Payments
$140.15
7 reported records · 6 companies
Healthcare provider profile · identity verified
Stacey King, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ROBERTSDALE, AL · NPI 1598146631
Verified facts
What the public records show
CMS Open Payments records show Stacey King, NP received $140.15 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.58 | 31.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.94 | 17.8% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $20.73 | 14.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.01 | 12.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.84 | 12.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.05 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.15 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 179 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 336 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 77 |
| Lisinopril | Lisinopril | 226 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 79 |
| Omeprazole | Omeprazole | 210 | 72 |
| Mounjaro | Tirzepatide | 179 | 39 |
| Metformin Hcl | Metformin Hcl | 159 | 47 |
| Losartan Potassium | Losartan Potassium | 145 | 56 |
| Trazodone Hcl | Trazodone Hcl | 117 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 43 |
| Ozempic | Semaglutide | 102 | 27 |
| Meloxicam | Meloxicam | 99 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 36 |
| Simvastatin | Simvastatin | 87 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 28 |
| Bupropion Xl | Bupropion Hcl | 78 | 25 |
| Jardiance | Empagliflozin | 78 | 27 |
| Montelukast Sodium | Montelukast Sodium | 77 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 23 |
| Potassium Chloride | Potassium Chloride | 75 | 19 |
| Farxiga | Dapagliflozin Propanediol | 74 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 24 |
| Azithromycin | Azithromycin | 67 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 34 |
| Prednisone | Prednisone | 67 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 20 |
| Ibuprofen | Ibuprofen | 61 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 28 |
| Buspirone Hcl | Buspirone Hcl | 59 | 20 |
| Sertraline Hcl | Sertraline Hcl | 57 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 18 |
| Trulicity | Dulaglutide | 54 | 12 |
| Irbesartan | Irbesartan | 53 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | 14 |
| Furosemide | Furosemide | 52 | 20 |
| Famotidine | Famotidine | 51 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 18 |
| Ondansetron Odt | Ondansetron | 48 | 21 |
| Ezetimibe | Ezetimibe | 47 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Lovastatin | Lovastatin | 42 | 12 |
| Eliquis | Apixaban | 41 | 11 |
| Estradiol | Estradiol | 41 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Carvedilol | Carvedilol | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 24 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Nystatin | Nystatin | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Alendronate Sodium | Alendronate Sodium | 28 | 12 |
| Finasteride | Finasteride | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.15 · 7 records | Lilly USA, LLC | Azstarys, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error